Drug Shortage Report for TEVA-IRBESARTAN HCTZ
Report ID | 101725 |
Drug Identification Number | 02330512 |
Brand name | TEVA-IRBESARTAN HCTZ |
Common or Proper name | IRBESARTAN/HCTZ 150/12.5MG TAB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | HYDROCHLOROTHIAZIDE IRBESARTAN |
Strength(s) | 12.5MG 150MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 100 |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2019-12-18 |
Estimated end date | 2021-09-30 |
Actual end date | 2021-09-09 |
Shortage status | Resolved |
Updated date | 2021-09-10 |
Company comments | Allocating 100% of Teva market share from July to October 2020. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v14 | 2020-05-01 | French | Compare |
v13 | 2020-05-01 | English | Compare |
v12 | 2020-04-23 | French | Compare |
v11 | 2020-04-23 | English | Compare |
v10 | 2020-04-09 | French | Compare |
v9 | 2020-04-09 | English | Compare |
v8 | 2020-03-05 | French | Compare |
v7 | 2020-03-05 | English | Compare |
v6 | 2020-01-30 | French | Compare |
v5 | 2020-01-30 | English | Compare |
v4 | 2020-01-09 | French | Compare |
v3 | 2020-01-09 | English | Compare |
v2 | 2019-12-19 | French | Compare |
v1 | 2019-12-19 | English | Compare |